The major role of androgens in prostate cancer and the need for more efficient blockade

References

• Lichtenberg F. Measuring the health impacts of medical innovation and expenditure. In: Health Services Research Seminal Series 2002–2003. University of Minnesota, Minneapolis, MN, USA (2002).
   Google Scholar
• Labrie F, Bélanger A, Cusan L et al. Antifertility effects of LHRH agonists in the male. J. Androl.1, 209–228 (1980).
   Google Scholar
• Labrie F, Dupont A, Bélanger A. Complete androgen blockade for the treatment of prostate cancer. In: Important Advances in Oncology. de Vita VT, Hellman S, Rosenberg SA (Eds). JB Lippincott, PA, USA, 193–217 (1985).
   Google Scholar
• Labrie F. Multiple intracrine hormonal targets in the prostate: opportunities and challenges. BJU Int.100(Suppl. 2), 48–51 (2007).
   PubMedGoogle Scholar
• Arnst C. Developments to watch. Why did prostate cancer death rates fall? Business Week92, 3853 (2003).
   Google Scholar
• Peto R, Dalesio O. Breast and prostate cancer: 10-year survival gains in the hormonal adjuvant treatment trials. Eur. J. Cancer Suppl.1, S101 (Abstract 32B) (2003).
   Google Scholar
• Labrie F, Cusan L, Gomez JL et al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J. Steroid Biochem. Mol. Biol.113, 52–56 (2009).
   PubMed Web of Science ®Google Scholar
• Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology60(1), 115–119 (2002).
   PubMedGoogle Scholar
• Akaza H, Hinotsu S, Usami M et al. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J. Urol.176(6 Pt 2), S47–S49 (2006).
   Google Scholar
• Ueno S, Namiki M, Fukagai T, Ehara H, Usami M, Akaza H. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int. J. Urol.13(12), 1494–1500 (2006).
   PubMedGoogle Scholar
• Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med.321(7), 419–424 (1989).
   PubMed Web of Science ®Google Scholar
• Denis LJ, Keuppens F, Smith PH et al. Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. Eur. Urol.33, 144–151 (1998).
   PubMed Web of Science ®Google Scholar
• Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis.2, 4–8 (1999).
   PubMed Web of Science ®Google Scholar
• Prostate Cancer Triallists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet355, 1491–1498 (2000).
   PubMed Web of Science ®Google Scholar
• Labrie F, Veilleux R. A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate8, 293–300 (1986).
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Giguère M et al. Benefits of combination therapy with Flutamide in patients relapsing after castration. Br. J. Urol.61, 341–346 (1988).
   PubMedGoogle Scholar
• Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Response to Flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol.150, 908–913 (1993).
   PubMed Web of Science ®Google Scholar
• Collinson MP, Daniel F, Tyrrell CJ, Teasdale C. Response of carcinoma of the prostate to withdrawal of flutamide. Br. J. Urol.72(5 Pt 1), 662–663 (1993).
   PubMedGoogle Scholar
• Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol.149, 607–609 (1993).
   PubMed Web of Science ®Google Scholar
• Labrie F, Veilleux R, Fournier A. Low androgen levels induce the development of androgen-hypersensitive cells clones in Shionogi mouse mammary carcinoma cells in culture. J. Natl Cancer Inst.80, 1138–1147 (1988).
   PubMedGoogle Scholar
• Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med.10(1), 33–39 (2004).
   PubMed Web of Science ®Google Scholar
• Mulders PF, Schalken JA. Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis.12(3), 241–246 (2009).
   PubMed Web of Science ®Google Scholar
• McPhaul MJ. Mechanisms of prostate cancer progression to androgen independence. Best Pract. Res. Clin. Endocrinol. Metab.22(2), 373–388 (2008).
   PubMed Web of Science ®Google Scholar
• Labrie C, Bélanger A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology123, 1412–1417 (1988).
   PubMed Web of Science ®Google Scholar
• El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F, Pelletier G. Localization of type 5 17β-hydroxysteroid dehydrogenase, 3β-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology140(3), 1481–1491 (1999).
   PubMedGoogle Scholar
• Nakamura Y, Suzuki T, Nakabayashi M et al. In situ androgen producing enzymes in human prostate cancer. Endocr. Relat. Cancer12(1), 101–107 (2005).
   PubMed Web of Science ®Google Scholar
• Rosner JM, Macome JC, Cardinali DP. In vitro biosynthesis of sterols and steroids by rat submaxillary glands. Endocrinology85, 1000–1003 (1969).
   PubMedGoogle Scholar
• Voutilainen R, Miller WL. Developmental expression of genes for the stereoidogenic enzymes P450scc (20,22-desmolase), P450c17 (17 α-hydroxylase/17,20-lyase), and P450c21 (21-hydroxylase) in the human fetus. J. Clin. Endocrinol. Metab.63(5), 1145–1150 (1986).
   PubMed Web of Science ®Google Scholar
• Akaza H, Yamaguchi A, Matsuda T et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J. Clin. Oncol.34(1), 20–28 (2004).
   PubMed Web of Science ®Google Scholar
• Dupont A, Labrie F, Giguere M et al. Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma. Eur. J. Cancer Clin. Oncol.24(4), 659–666 (1988).
   PubMedGoogle Scholar
• Dupont A, Cusan L, Gomez JL et al. Combination therapy with flutamide and the LHRH agonist [D-Trp6-des-Gly-NH2]LHRH ethylamide in stage C prostatic carcinoma. Br. J. Urol.72, 629–634 (1993).
   PubMedGoogle Scholar
• Labrie F, Simard J, Singh SM, Candas B. Estimated potency of Casodex: a problematic design. Urology50, 309–313 (1997).
   PubMedGoogle Scholar
• Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med.351(15), 1488–1490 (2004).
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science324(5928), 787–790 (2009).
   PubMed Web of Science ®Google Scholar
• Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol.28(9), 1489–1495 (2010).
   PubMed Web of Science ®Google Scholar
• Attard G. Selective inhibition of CYP17 with abiraterone acetate is highly active incastration-resistant prostate cancer. Presented at: 14th International Congress on Hormonal Steroids and Hormones & Cancer. Edinburgh, UK, September 21–24 2010.
   Google Scholar
• Labrie F. Hormonal therapy of prostate cancer. In: Neuroendocrinology, The Normal Neuroendocrine System. Progress in Brain Research. Martini L, Chrousos GP, Labrie F, Pacak K, Pfaff DW (Eds). Elsevier, Amsterdam, The Netherlands, 321–341 (2010).
   Google Scholar
• Labrie F. Intracrinology. Mol. Cell. Endocrinol.78, C113–C118 (1991).
   PubMed Web of Science ®Google Scholar
• Labrie F, Candas B, Cusan L et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology47, 212–217 (1996).
   PubMedGoogle Scholar